Similar articles

• Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease after treatment with galantamine.

  Erkinjuntti T. Erkinjuntti T. Eur J Neurol. 2002 Sep;9(5):545. doi: 10.1046/j.1468-1331.2002.04455.x. Eur J Neurol. 2002. PMID: 12220392 No abstract available.
• [Galantamine (reminyl) in the treatment of Alzheimer's disease and vascular dementia].

  Gavrilova SI, Zharikov GA. Gavrilova SI, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2003;103(12):59-65. Zh Nevrol Psikhiatr Im S S Korsakova. 2003. PMID: 14763262 Review. Russian. No abstract available.
• Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial.

  Marder K. Marder K. Curr Neurol Neurosci Rep. 2002 Sep;2(5):389-90. doi: 10.1007/s11910-002-0062-x. Curr Neurol Neurosci Rep. 2002. PMID: 12169216 Clinical Trial. No abstract available.
• Galantamine: a review of its use in Alzheimer's disease and vascular dementia.

  Corey-Bloom J. Corey-Bloom J. Int J Clin Pract. 2003 Apr;57(3):219-23. Int J Clin Pract. 2003. PMID: 12723727 Review.
• Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.

  Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Erkinjuntti T, et al. Lancet. 2002 Apr 13;359(9314):1283-90. doi: 10.1016/S0140-6736(02)08267-3. Lancet. 2002. PMID: 11965273 Clinical Trial.